Sodium Iodide → 3-[1-({2-[(4-hydroxycyclohexyl)amino]ethyl}sulfonyl)-4-piperidinyl]-5-(3-thienyl)-1H-indole-7-carboxamide

HRID 2267527Notes

Reaction equation

HRID 2267527 reaction equation
NS(N)(=O)=O.Cl[CH2:7][CH2:8][S:9]([N:12]1[CH2:17][CH2:16][CH:15]([C:18]2[C:26]3[C:21](=[C:22]([C:32]([NH2:34])=[O:33])[CH:23]=[C:24]([C:27]4[CH:31]=[CH:30][S:29][CH:28]=4)[CH:25]=3)[NH:20][CH:19]=2)[CH2:14][CH2:13]1)(=[O:11])=[O:10].[NH2:35][CH:36]1[CH2:41][CH2:40][CH:39]([OH:42])[CH2:38][CH2:37]1.C([O-])([O-])=O.[K+].[K+].[Na+].[I-]>>[OH:42][CH:39]1[CH2:40][CH2:41][CH:36]([NH:35][CH2:7][CH2:8][S:9]([N:12]2[CH2:17][CH2:16][CH:15]([C:18]3[C:26]4[C:21](=[C:22]([C:32]([NH2:34])=[O:33])[CH:23]=[C:24]([C:27]5[CH:31]=[CH:30][S:29][CH:28]=5)[CH:25]=4)[NH:20][CH:19]=3)[CH2:14][CH2:13]2)(=[O:11])=[O:10])[CH2:37][CH2:38]1

Participants

6

Procedure

Following the general procedure for aminosulfonamide formation outlined in example 2, 3-{1-[(2-chloroethyl)sulfonyl]-4-piperidinyl}-5-(3-thienyl)-1H-indole-7-carboxamide (0.09 mmol) and 4-aminocyclohexanol (33.4 mg, 0.45 mmol) were allowed to react in the presence of K2CO3 (44 mg, 0.45 mmol) and NaI (Cat. 5 mg). The resulting residue was purified by reverse phase HPLC eluting with 10% B to 80% B, where A=H2O (0.1% trifluoroacetic acid) and B=CH3CN (0.1% trifluoroacetic acid) to give the title compound (3.6 mg, 7.7%).

Workup

  1. customThe resulting residue was purified by reverse phase HPLC
  2. washeluting with 10% B to 80% B, where A=H2O (0.1% trifluoroacetic acid) and B=CH3CN (0.1% trifluoroacetic acid)

Sources & evidence

ORD record
ord-fedeb598be3c4eb0b2dc1bd59e50af00
Source dataset
uspto-grants-2010_12
Patent number
US07858796B2

Reaction notes

Loading…